|
Smallpox Vaccine Adverse Events Among Civilians --- United States,
January 24--February 18, 2003
During the civilian smallpox vaccination program, CDC and state health
departments are conducting surveillance for vaccine-associated adverse
events. In the first stage of the program, active surveillance is being
conducted for potentially life-threatening, moderate-to-severe, and other
serious adverse events and for vaccinia transmission to contacts of
vaccinees (1)
(Table). Nonserious events are reported via passive
surveillance and are expected to be underreported. This report summarizes
smallpox vaccine adverse events reported among civilians vaccinated as of
February 14, 2003, and received by CDC from the Vaccine Adverse Event
Reporting System (VAERS) as of February 18.
Potentially life-threatening and moderate-to-serious events are
classified on the basis of evidence in support of the reported diagnoses.
For probable cases, other causes are excluded, and supportive information is
available. Events are classified as suspected if they have clinical features
compatible with the diagnosis but either further investigation is required
or additional investigation of the case did not provide supporting evidence
for the diagnosis and did not identify an alternative diagnosis. CDC and
state health departments also receive reports of other events that are
associated temporally with smallpox vaccination. Reported adverse events are
not necessarily associated with vaccination, and some or all of these events
might be coincidental.
During January 24--February 14, 2003, smallpox vaccine was administered
to 4,213 civilian health-care workers in 27 jurisdictions. No potentially
life threatening or moderate-to-severe adverse events have been reported.
Among seven vaccinees with reported nonserious adverse events, the most
common signs and symptoms were fever (n = two), rash (n = two), malaise (n =
two), pruritus (n = two), hypertension (n = two), and pharyngitis (n = two).
Surveillance for adverse events during the civilian smallpox vaccination
program is ongoing. Regular surveillance reports will be published in
MMWR.
Reference
- CDC.
Smallpox Vaccine Adverse Events Monitoring and Response System for the
first stage of the smallpox vaccination program. MMWR 2002;52:88--9.
Use of trade names and commercial sources is for
identification only and does not imply endorsement by the U.S.
Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service
to MMWR readers and do not constitute or imply endorsement of
these organizations or their programs by CDC or the U.S. Department of
Health and Human Services. CDC is not responsible for the content of
pages found at these sites. URL addresses listed in MMWR were
current as of the date of publication.
|
All MMWR HTML versions of articles are electronic
conversions from ASCII text into HTML. This conversion may have resulted in
character translation or format errors in the HTML version. Users should not
rely on this HTML document, but are referred to the electronic PDF version
and/or the original MMWR paper copy for the official text, figures,
and tables. An original paper copy of this issue can be obtained from the
Superintendent of Documents, U.S. Government Printing Office (GPO),
Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for
current prices.
**Questions or messages regarding errors in formatting should be
addressed to mmwrq@cdc.gov.
Page converted: 2/20/2003
|
|